HealthCare Global Enterprises Ltd. reports Q3 FY22 results reflecting a year-on-year growth of 7%. With 25 hospitals, 21 of which are Oncology focused, HealthCare Global Enterprises has built a niche platform in the Indian healthcare space.
Bengaluru : HealthCare Global Enterprises Limited (“HCG”), the leader in India in speciality healthcare services focused on oncology and fertility has announced its financial results for the quarter (“Q3”) and nine months ended December 31, 2021. Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “We are happy to report a robust Q3 FY 22 with secular growth across regions and segments. The last six years as a publicly listed company have seen a sustained growth in footfalls and revenues. Our new patient registration has almost doubled since 2018 and we currently are above 100,000 new patients per annum which in turn has doubled the revenue in the said period.”
Adding further he said “The fact that 85% of this revenue is Oncology centric is a clear testament of our business model in addition to the deep social impact that we make to the lives of thousands of patients and their families. Looking at the future, we believe that this growth will enhance not only on the back of the increasing longevity of patients but also a realization that cancer is now being viewed as a curable and chronic disease with a good lifestyle. With the addition of the labs and the clinical trials business, we are now uniquely positioned to not only enhance our diagnostic capabilities and offerings but potentially redefine precision medicine with end-to-end expertise spanning bioinformatics, genomics and research. With 25 hospitals, 21 of which are Oncology focused, we have built a niche platform in the Indian healthcare space and with our major capex cycles already done, I believe the future years will see the Company benefiting from these investments.”
Highlights for quarter ended December 31, 2021
1. Consolidated Income from Operations (“Revenue”) was INR 3,581 mn as compared to INR 2,740 mn in the corresponding quarter of the previous year, reflecting a year-on-year growth of 7%
2. Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was INR 648 mn, as compared to INR 437 mn in the corresponding quarter of the previous year, a growth of 4% year-on-year
3. Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was INR 619 mn, as compared to INR 378 mn in the corresponding quarter of the previous year, a growth of 5% year-on-year
4. Operating EBITDA for Existing centers was INR 566 mn, a growth of 8% year-on-year, reflecting an Operating EBITDA margin of 20.6%
5. Operating EBITDA from New centers was INR 52 mn, as compared to loss of INR 21 mn in the corresponding quarter of the previous year
6. Proforma PAT was INR 12 mn, as compared to a loss of INR 205 mn in the corresponding quarter of last year, after adjusting below and tax implications there of;
- Impairment of NCR Project of INR 472 Mn
- Exceptional gain of INR 19 Mn arising out of Suchirayu acquisition
- Onetime project fee of Q3’22 INR 20 Mn
(INR million except earnings per share)
| Period ended Dec’21 | Q3-FY22 | Q3-FY21 | Growth (y-o-y) |
|||||
| Income from Operations | 3,581 | 2,740 | 30.7% | |||||
| EBITDA(1) | 648 | 437 | 48.4% | |||||
| EBITDA margin (%) | 18.1% | 15.9% | ||||||
| Operating EBITDA (2) | 619 | 378 | 63.5% | |||||
| Op. EBITDA margin (%) | 17.3% | 13.8% | ||||||
| PBT (3) | (461) | (354) | NM | |||||
| PBT margin % | -12.9% | -12.9% | ||||||
| PAT (4) | (458) | (293) | NM | |||||
| PAT margin % | -12.8% | -10.7% | ||||||
| Earnings per share (EPS) | (3.55) | (2.33) | NM | |||||
| Proforma PAT | 12 | (205) | NM | |||||
- Profit before depreciation and amortization, finance costs, exceptional items and taxes
- EBITDA excluding other Income and Includes new ESOP scheme expenses 17 Mn and one-time project expense of 20 Mn Q3’22
- Profit / (Loss) before tax and after share of profit / (loss) of equity accounted Q3’22 Adjusted for impairment of NCR project of INR 472 Mn and exceptional gain of INR 19 Mn arising out of Suchirayu acquisition
- Profit / (Loss) for the period after share of profit / (loss) of equity accounted investee, taxes and minority interests
- Proforma PAT is after normalizing for one-time project expense, impairment loss and exceptional gain and tax implications there of
Business Updates for Q3 FY22
- Record performance with ‘all-time high’ operating financials delivered across the business:
- Highest ever quarterly Revenue and Operating EBITDA delivered during the quarter
- Strong yearly revenue growth on the back of higher footfalls
- HCG New centers continued their scale-up trajectory:
- Strong revenue growth of 2% y-o-y
- Recorded positive EBITDA with several centers witnessing turnaround in EBITDA (unit level)
- Several regions delivered high double-digit revenue growth on yearly basis on the back of gradual unlocking of the economy
- Maharashtra upsurge continued across all centers and delivered 9% revenue growth y-o-y
- East India witnessed a continuance in its growth path with 1% revenue growth y-o-y
- North India recorded a high growth of 9% y-o-y
- Other highlights
- Milann revenues grew by 5% y-o-y and our digital campaigns contributed to this
Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd, added, “We have delivered another quarter of sustained performance. This was our fourth consecutive quarter with all-time-record revenue and second consecutive quarter with all-time-record EBIDTA. Implementation of go-to-market plans across our network locations during last three quarters have started showing results through this profitable growth. Overall, these results were made possible through execution focus and hard work of entire HCG team and we remain committed to driving growth and optimizing operations in the coming quarters. As we look to the future, we want to build a long-term relationship with our patients to be their trusted advisor over a lifetime. With that objective in mind, we have begun our digital transformation journey to create an Omni-channel end to end patient engagement platform with the help of digital technology. We believe that this initiative will accelerate our growth in future and help HCG to solidify its leadership position in oncology.”
